Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by fairfax1on May 27, 2010 11:58am
249 Views
Post# 17136399

Don't agree fully about the volume point

Don't agree fully about the volume pointSure only about 30/150 mil have been traded, and even amongst those 30 mil traded probably a third or so are the same shares. Still, over 10% of the company is traded, and that is substantial. The way I see it the big shareholders have no option but to hold, even if they want out after the news. If they sold, there are simply not enough buyers, selling by them would cause the price  to retreat into the < 5 cent range. Also, the test results are not fully understood - they can't risk selling yet.
Bullboard Posts